{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:41:20Z","timestamp":1778503280619,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T00:00:00Z","timestamp":1549584000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006087","name":"Direcci\u00f3n General de Asuntos del Personal Acad\u00e9mico, Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","award":["by PAPIIT IN224617"],"award-info":[{"award-number":["by PAPIIT IN224617"]}],"id":[{"id":"10.13039\/501100006087","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006087","name":"Direcci\u00f3n General de Asuntos del Personal Acad\u00e9mico, Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","award":["PAPIIT IN224116"],"award-info":[{"award-number":["PAPIIT IN224116"]}],"id":[{"id":"10.13039\/501100006087","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13048-019-0486-4","type":"journal-article","created":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T13:32:11Z","timestamp":1549632731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Progesterone reduces cell survival in primary cultures of endometrioid ovarian cancer"],"prefix":"10.1186","volume":"12","author":[{"given":"Enrique","family":"Pedernera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda J.","family":"G\u00f3mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Morales-V\u00e1squez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delia","family":"P\u00e9rez-Montiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8342-3927","authenticated-orcid":false,"given":"Carmen","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,8]]},"reference":[{"issue":"Suppl 1","key":"486_CR1","doi-asserted-by":"publisher","first-page":"S161","DOI":"10.1016\/S0020-7292(06)60033-7","volume":"95","author":"A Heintz","year":"2006","unstructured":"Heintz A, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. Int J Gynaecol Obstet. 2006;95(Suppl 1):S161\u2013S92.","journal-title":"Int J Gynaecol Obstet"},{"key":"486_CR2","unstructured":"Kurman RJ. International Agency for Research on Cancer., World Health Organization. WHO classification of tumours of female reproductive organs. Lyon: International Agency for Research on Cancer. 2014:307."},{"key":"486_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13048-016-0247-6","volume":"9","author":"F Morales-Vasquez","year":"2016","unstructured":"Morales-Vasquez F, Pedernera E, Reynaga-Obregon J, Lopez-Basave HN, Gomora MJ, Carlon E, et al. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma. J Ovarian Res. 2016;9:41.","journal-title":"J Ovarian Res."},{"key":"486_CR4","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","volume":"387","author":"IJ Jacobs","year":"2016","unstructured":"Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK collaborative trial of ovarian Cancer screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387:945\u201356.","journal-title":"Lancet"},{"key":"486_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1001\/jama.2017.21421","volume":"319","author":"JT Henderson","year":"2018","unstructured":"Henderson JT, Webber EM, Sawaya GF. Screening for ovarian Cancer: updated evidence report and systematic review for the US preventive services task force. JAMA. 2018;319:595\u2013606.","journal-title":"JAMA"},{"key":"486_CR6","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20170571","volume":"91","author":"R Kamal","year":"2018","unstructured":"Kamal R, Hamed S, Mansour S, Mounir Y, Abdel Sallam S. Ovarian cancer screening-ultrasound; impact on ovarian cancer mortality. Br J Radiol. 2018;91:20170571.","journal-title":"Br J Radiol"},{"key":"486_CR7","doi-asserted-by":"publisher","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. https:\/\/doi.org\/10.3322\/caac.21492 .","DOI":"10.3322\/caac.21492"},{"key":"486_CR8","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ygyno.2009.05.045","volume":"114","author":"H Arias-Pulido","year":"2009","unstructured":"Arias-Pulido H, Smith HO, Joste NE, Bocklage T, Qualls CR, Chavez A, et al. Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol. 2009;114:480\u20135.","journal-title":"Gynecol Oncol"},{"key":"486_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/IGC.0b013e3182788466","volume":"23","author":"D Zhao","year":"2013","unstructured":"Zhao D, Zhang F, Zhang W, He J, Zhao Y, Sun J. Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2013;23:25\u201333.","journal-title":"Int J Gynecol Cancer"},{"key":"486_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/srep25408","volume":"6","author":"Z Feng","year":"2016","unstructured":"Feng Z, Wen H, Bi R, Ju X, Chen X, Yang W, et al. A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression. Sci Rep. 2016;6:25408.","journal-title":"Sci Rep"},{"key":"486_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/10937400701876095","volume":"11","author":"F Salehi","year":"2008","unstructured":"Salehi F, Dunfield L, Phillips KP, Krewski D, Vanderhyden BC. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev. 2008;11:301\u201321.","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"486_CR12","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","volume":"14","author":"W Sieh","year":"2013","unstructured":"Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study. Lancet Oncol. 2013;14:853\u201362.","journal-title":"Lancet Oncol"},{"key":"486_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ygyno.2004.11.010","volume":"96","author":"P Lee","year":"2005","unstructured":"Lee P, Rosen DG, Zhu C, Silva EG, Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol. 2005;96:671\u20137.","journal-title":"Gynecol Oncol"},{"key":"486_CR14","first-page":"1051","volume":"18","author":"EV Hogdall","year":"2007","unstructured":"Hogdall EV, Christensen L, Hogdall CK, Blaakaer J, Gayther S, Jacobs IJ, et al. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep. 2007;18:1051\u20139.","journal-title":"Oncol Rep"},{"key":"486_CR15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/1471-2407-12-553","volume":"12","author":"M Lenhard","year":"2012","unstructured":"Lenhard M, Tereza L, Heublein S, Ditsch N, Himsl I, Mayr D, et al. Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. BMC Cancer. 2012;12:553.","journal-title":"BMC Cancer"},{"key":"486_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ygyno.2014.03.563","volume":"133","author":"K Matsuo","year":"2014","unstructured":"Matsuo K, Sheridan TB, Mabuchi S, Yoshino K, Hasegawa K, Studeman KD, et al. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Gynecol Oncol. 2014;133:473\u20139.","journal-title":"Gynecol Oncol"},{"key":"486_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1757-2215-3-14","volume":"3","author":"B Nodin","year":"2010","unstructured":"Nodin B, Zendehrokh N, Brandstedt J, Nilsson E, Manjer J, Brennan DJ, et al. Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. J Ovarian Res. 2010;3:14.","journal-title":"J Ovarian Res"},{"key":"486_CR18","doi-asserted-by":"crossref","first-page":"62400","DOI":"10.18632\/oncotarget.18253","volume":"8","author":"Z Shen","year":"2017","unstructured":"Shen Z, Luo H, Li S, Sheng B, Zhao M, Zhu H, et al. Correlation between estrogen receptor expression and prognosis in epithelial ovarian cancer: a meta-analysis. Oncotarget. 2017;8:62400\u201313.","journal-title":"Oncotarget"},{"key":"486_CR19","first-page":"3667","volume":"9","author":"AJ Li","year":"2003","unstructured":"Li AJ, Baldwin RL, Karlan BY. Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma. Clin Cancer Res. 2003;9:3667\u201373.","journal-title":"Clin Cancer Res"},{"key":"486_CR20","doi-asserted-by":"publisher","first-page":"8128","DOI":"10.1038\/sj.onc.1208959","volume":"24","author":"V Syed","year":"2005","unstructured":"Syed V, Zhang X, Lau KM, Cheng R, Mukherjee K, Ho SM. Profiling estrogen-regulated gene expression changes in normal and malignant human ovarian surface epithelial cells. Oncogene. 2005;24:8128\u201343.","journal-title":"Oncogene"},{"key":"486_CR21","first-page":"6768","volume":"61","author":"V Syed","year":"2001","unstructured":"Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res. 2001;61:6768\u201376.","journal-title":"Cancer Res"},{"key":"486_CR22","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1002\/(SICI)1097-0142(19970515)79:10<1944::AID-CNCR15>3.0.CO;2-V","volume":"79","author":"SZ Bu","year":"1997","unstructured":"Bu SZ, Yin DL, Ren XH, Jiang LZ, Wu ZJ, Gao QR, et al. Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer. 1997;79:1944\u201350.","journal-title":"Cancer"},{"key":"486_CR23","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.1038\/sj.onc.1206828","volume":"22","author":"V Syed","year":"2003","unstructured":"Syed V, Ho SM. Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL. Oncogene. 2003;22:6883\u201390.","journal-title":"Oncogene"},{"key":"486_CR24","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/sj.onc.1207991","volume":"24","author":"V Syed","year":"2005","unstructured":"Syed V, Mukherjee K, Lyons-Weiler J, Lau KM, Mashima T, Tsuruo T, et al. Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling. Oncogene. 2005;24:1774\u201387.","journal-title":"Oncogene"},{"key":"486_CR25","first-page":"1187","volume":"32","author":"M Valladares","year":"2017","unstructured":"Valladares M, Plaza-Parrochia F, Lepez M, Lopez D, Gabler F, Gayan P, et al. Effect of estradiol on the expression of angiogenic factors in epithelial ovarian cancer. Histol Histopathol. 2017;32:1187\u201396.","journal-title":"Histol Histopathol"},{"key":"486_CR26","first-page":"616","volume":"118","author":"A Werner","year":"1996","unstructured":"Werner A, Aichberger A, Krebs D. Does interferon-alpha enhance the effect of tamoxifen-medroxyprogesterone acetate and hydroxyflutamide on in vitro tumor cells? Zentralbl Gynakol. 1996;118:616\u201321.","journal-title":"Zentralbl Gynakol"},{"key":"486_CR27","first-page":"138","volume":"8","author":"W Remmele","year":"1987","unstructured":"Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8:138\u201340.","journal-title":"Pathologe"},{"key":"486_CR28","first-page":"70","volume":"2","author":"ISR Turin","year":"2014","unstructured":"Turin ISR, Maestri M, Luinetti O, Dal Bello B, Paulli M, et al. In vitro efficient expansion of tumor cells deriving from different types of human tumor samples. Med Sci. 2014;2:70\u201381.","journal-title":"Med Sci"},{"key":"486_CR29","doi-asserted-by":"crossref","unstructured":"Gomora MJ, Morales-Vasquez F, Pedernera E, Perez-Montiel D, Lopez-Basave H, Villa AR, et al. Sexual steroid hormone receptors profiles in ovarian carcinoma in Mexican women. Endocr Connect. 2018.","DOI":"10.1530\/EC-18-0158"},{"key":"486_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.steroids.2017.08.007","volume":"126","author":"F Plaza-Parrochia","year":"2017","unstructured":"Plaza-Parrochia F, Romero C, Valladares L, Vega M. Endometrium and steroids, a pathologic overview. Steroids. 2017;126:85\u201391.","journal-title":"Steroids"},{"key":"486_CR31","doi-asserted-by":"publisher","first-page":"R255","DOI":"10.1530\/ERC-12-0175","volume":"19","author":"F Modugno","year":"2012","unstructured":"Modugno F, Laskey R, Smith AL, Andersen CL, Haluska P, Oesterreich S. Hormone response in ovarian cancer: time to reconsider as a clinical target? Endocr Relat Cancer. 2012;19:R255\u201379.","journal-title":"Endocr Relat Cancer"},{"key":"486_CR32","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1530\/JME-14-0252","volume":"54","author":"CH Diep","year":"2015","unstructured":"Diep CH, Daniel AR, Mauro LJ, Knutson TP, Lange CA. Progesterone action in breast, uterine, and ovarian cancers. J Mol Endocrinol. 2015;54:R31\u201353.","journal-title":"J Mol Endocrinol"},{"issue":"18","key":"486_CR33","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1016\/j.celrep.2017.02.049","volume":"14","author":"NY Wu","year":"2017","unstructured":"Wu NY, Huang HS, Chao TH, Chou HM, Fang C, Qin CZ, et al. Progesterone prevents high-grade serous ovarian Cancer by inducing necroptosis of p53-defective fallopian tube epithelial cells. Cell Rep. 2017;14(18):2557\u201365.","journal-title":"Cell Rep"},{"key":"486_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.cca.2017.05.002","volume":"470","author":"G Eisenhofer","year":"2017","unstructured":"Eisenhofer G, Peitzsch M, Kaden D, Langton K, Pamporaki C, Masjkur J, et al. Reference intervals for plasma concentrations of adrenal steroids measured by LC-MS\/MS: Impact of gender, age, oral contraceptives, body mass index and bloodpressure status. Clin Chim Acta. 2017;470:115\u201324.","journal-title":"Clin Chim Acta."},{"key":"486_CR35","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature14583","volume":"523","author":"H Mohammed","year":"2015","unstructured":"Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, et al. Progesterone receptor modulates ERalpha action in breast cancer. Nature. 2015;523:313\u20137.","journal-title":"Nature"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0486-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-019-0486-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0486-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T04:00:28Z","timestamp":1606449628000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-019-0486-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,8]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["486"],"URL":"https:\/\/doi.org\/10.1186\/s13048-019-0486-4","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,8]]},"assertion":[{"value":"14 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by Ethical Committees of INCan (008\/034\/OMI) and UNAM (108\/2015).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"15"}}